Develops multifunctional RNA nanoparticles that specifically target a novel therapy resistance gene in breast cancer, using RNA nanotechnology to overcome treatment resistance. This approach improves therapeutic efficacy while minimizing side effects, providing a safer and more effective option for cancer patients.
Funding
Funding not disclosed
Founders
Product
Problem
Many breast cancers develop resistance to existing therapies, leading to treatment failure and disease progression. Overcoming this resistance requires targeting the underlying mechanisms that allow cancer cells to evade drug effects. Traditional cancer therapies often lack the specificity needed to target cancer cells effectively, resulting in off-target effects and toxicity.
Solution
RNA Nanotherapeutics develops multifunctional RNA nanoparticles designed to specifically target therapy resistance genes in breast cancer cells. Their RNA nanotechnology approach aims to overcome treatment resistance by delivering therapeutic payloads directly to cancer cells, improving efficacy while minimizing side effects. The nanoparticles are engineered to recognize and bind to specific markers on cancer cells, ensuring targeted delivery of the therapeutic RNA. This targeted approach aims to enhance the therapeutic index of cancer treatments, providing a safer and more effective option for patients.
Target Audience
The primary target audience includes breast cancer patients who have developed resistance to traditional therapies, as well as oncologists and researchers seeking more effective and targeted treatment options.
Features
- RNA-nanotechnology-based approach for targeted drug delivery
- Multifunctional RNA nanoparticles designed to overcome treatment resistance
- Specific targeting of therapy resistance genes in breast cancer cells
- Improved therapeutic efficacy with minimal side effects